Invitae Files Patent Infringement Suit Against Myriad Genetics

Invitae Corporation today announced that it filed an action in the U.S. District Court for the Northern District of California against Myriad Genetics, Inc. MYGN. By its suit, Invitae seeks a declaration that certain Myriad patents relating to the BRCA1/2 and MUTYH genes are invalid and are not infringed by Invitae. Invitae's announcement today reinforces its commitment to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients (see Invitae Responds to Myriad Genetics Lawsuit). Earlier this year, the Supreme Court ruled that naturally occurring DNA and the information it encodes cannot be patented (Assn'n for Molecular Pathology v. Myriad Genetics, Inc., 133 See full press release